BACKGROUND: Spine and nonspine skeletal metastases occur in more than 80% of patients with prostate cancer. OBJECTIVE: To examine the characteristics of the patient population undergoing surgery for the treatment of prostate cancer metastatic to the spine. METHODS: A retrospective chart review was performed on all patients treated at our institution from June 1993 to August 2014 for surgical management of metastatic spine disease from prostate cancer. RESULTS: During the study period, 139 patients with 157 surgical lesions underwent surgery for metastatic spine disease. Decompression for high-grade epidural spinal cord compression was required for 126 patients with 143 lesions. Preoperatively, 69% had a motor deficit and 21% were nonambulatory, with 32% due to motor weakness. At surgery, 87% of patients had hormone-refractory prostate cancer (HRPC) and 61% failed prior radiation. Median overall survival for HRPC patients was 6.6 mo (95% confidence interval [CI]: 5.6-8.6) while the median overall survival for hormone-sensitive patients was 16.3 mo (95% CI: 4.0-26.6).
S
pine and nonspine skeletal metastases occur in more than 80% of patients with advanced prostate cancer.
1,2 Metastatic spine disease (MSD) from prostate cancer ABBREVIATIONS: ADT, androgen deprivation therapy; cEBRT, conventional external beam radiation; CI, confidence interval; CSF, cerebrospinal fluid; ESCC, epidural spinal cord compression; HRPC, hormone-refractory prostate cancer; MRI, magnetic resonance imaging; MSD, metastatic spine disease; OS, overall survival; PSA, prostate-specific antigen; RT, radiation therapy; SRS, stereotactic radiosurgery may present as a pathological fracture with or without high-grade epidural spinal cord compression (ESCC) or mechanical instability causing pain; in a number of patients, however, MSD may be the presenting feature of newly diagnosed prostate cancer. 3, 4 The osteoblastic lesions typical of metastatic prostate cancer are considered radiosensitive. 5 Therefore, surgical treatment is reserved for treating symptomatic high-grade ESCC in a previously irradiated field or pathological fractures resulting in mechanical instability. 6, 7 At the time of diagnosis, the majority of prostate cancer is hormone sensitive and responds well to androgen deprivation. In fact, concomitant hormone therapy with conventional external beam radiation (cEBRT) has been explored as a first line of treatment even for high-grade ESCC from newly diagnosed prostate cancer. 8 While androgen deprivation is very effective in treating hormonenaïve prostate cancer, 9 death from prostate cancer typically results from the systemic spread of hormone-resistant cells. 9, 10 A few studies have looked at the effectiveness of surgical decompression in the setting of high-grade ESCC from prostate metastasis with favorable outcomes. 5, [11] [12] [13] [14] [15] [16] However, the experience in these studies has been limited due to small sample sizes. In this study, we examine the largest cohort of patients to date who underwent surgical decompression for metastatic prostate cancer to the spine. The purpose of this study was to delineate the patient population requiring spinal surgery for metastatic prostate cancer and to report the surgical outcomes in this patient population.
METHODS

Patient Selection
A retrospective chart review was performed on all patients treated at a single academic medical center from June 1993 to August 2014 for surgical management of spinal metastases from prostate cancer. The review was conducted under IRB Research Protocol #WA0329-14. Patient consent was not required. During this period, all patients with histologically confirmed prostate cancer with MSD causing rapidly progressive neurological deterioration and/or mechanical instability and who were medically able to tolerate surgery were included in the study. Patients with a life expectancy of less than 3 mo or who were treated with chemoradiation alone were excluded ( Figure 1 ).
Clinical Data
Medical records were reviewed for demographics, diagnosis of primary disease, diagnosis of MSD, time to progression, hormone response status at the time of MSD and spine surgery, prostate-specific antigen (PSA) levels, preoperative treatment, decision making for surgical decompression (neurological, oncologic, or mechanical instability), extent of disease, postoperative treatment (chemoradiation), and follow-up. The degree of ESCC and mechanical instability were noted from available radiographic data and clinical information. For radiation, both the dose and fractionation schemes were recorded. Pathological data included Gleason score and histological variant of prostate cancer. Complications from surgery that required outpatient treatment, readmission, or reoperation, including infection, wound dehiscence, cerebrospinal fluid (CSF) leak, epidural hematoma, and hardware failure, were recorded.
Surgical Decision Making
The need for surgical intervention was dictated by the patient's neurological and oncologic disease burden as well as evidence of mechanical instability, previously described as the NOMS (Neurologic, Oncologic, Mechanical instability, and Systemic disease) framework. The type of surgery, including anterior/posterior decompression, with or without instrumentation, and the number of levels instrumented was documented.
The majority of patients in our study underwent separation surgery. Resection of epidural disease was facilitated by this approach, in which the laminae, pedicles, and facet joints are removed over the levels affected by the ESCC. In rare instances, the vertebral body disease was lytic rather than sclerotic. In some of those cases, the diseased bone was resected from a posterior transpedicular approach and the vertebral body was replaced with polymethyl methacrylate augmented with Steinmann pins. Posterior segmental fixation was provided with pedicle screws in the thoracic and lumbar spine and with lateral mass screws in the cervical spine.
Postoperative Radiation
The majority of radiation naïve patients underwent postoperative radiation using cEBRT, most commonly 30 Gy in 10 fractions 17, 18 or 24-Gy single-fraction stereotactic radiosurgery (SRS). Patients who failed prior radiation were reirradiated using a high-dose hypofractionated SRS with doses ranging from 18 to 36 Gy in 3 to 6 fractions. In patients undergoing SRS, postoperative computed tomography myelography was performed to delineate spinal cord and dural margins as well as to avoid any radiographic artifact encountered on magnetic resonance imaging (MRI) in the setting of proximate spinal instrumentation. The myelography and simulation were often performed prior to patient discharge following surgery.
Clinical Outcomes
Patients' ambulatory, bowel, bladder, and neurological statuses were recorded pre-and postoperatively. The postoperative assessments were recorded at 3 mo and at the last follow-up visit. Assessment of neurological status included motor or sensory deficits and mechanical pain.
Statistical Analysis
Descriptive statistics such as frequencies, medians, and interquartile ranges were utilized. McNemar's test was used to examine associations of paired pre-and postsurgical data. Overall survival (OS) was calculated from time of surgery to date of last follow-up or date of death. All P values were 2-sided and all statistical analyses and graphics were performed in SAS version 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
Patient Characteristics
One hundred thirty-nine patients underwent 157 spine operations related to MSD due to prostate cancer. The median age at diagnosis of MSD was 65 yr (range: 41-89 yr), while that at surgery was 68 yr (range: 45-90 yr; Table 1 ). The median overall follow-up from surgery was 6.7 mo (range: 0.3-143.1 mo), while that for survivors was 8.1 mo (range: 1.2-67.2 mo). The median time from MSD diagnosis to surgery was 21.1 mo (range: 0-194.5 mo). The median Gleason score at the time of the prostate cancer diagnosis was 7.5 (range: 5-10), and all but 1 patient had a Gleason score greater than 6. The median PSA level was 18.2 ng/mL (range: 0.2-13 010) at spine diagnosis and 52.0 ng/mL (range: 0.05-3999) at surgery. In terms of responsiveness to hormones, 87% (121/139) of patients were hormone refractory at the time of surgery. Over 95% (133/139) of all patients had prostate adenocarcinoma with classic acinar histology, while 4% (6/139) had nonacinar (small cell) histology. 
Management of Primary and MSD
In addition to standard hormone depletion therapy, 42% (66/157) of patients also received treatment with bisphosphonates. Surgical orchiectomy was performed in 6% (9/157) of patients. The median time from diagnosis of prostate carcinoma to MSD was 40.8 mo (range: 0-209.7 mo). MSD was single level in 35% (48/139) of patients, involved 2 to 4 levels in 27% (38/139) of patients, and involved >5 levels in 36% (50/139) of patients, while extent of disease was unknown in 2% (3/139). Of the 148 unique lesions, 61% (90/139) received radiation therapy (RT) after diagnosis of MSD. Of these lesions, 86% (77/90) received cEBRT with a median dose of 3000 cGy in 10 fractions (range: 2400-5760 cGy), 7.8% (7/90) received single-fraction SRS with a median dose of 2400 cGy (range: 1800-2400 cGy), 7.8% (7/90) received hypofractionated SRS with a median dose of 2500 cGy in 5 fractions (range: 2000-3900 cGy in 3-5 fractions), and 2% (2/90) received RT of an unknown type at outside institutions.
Hormone Responsiveness at MSD and at Time of Surgery
At the time of MSD diagnosis, 44% (61/139) of patients demonstrated hormone-refractory prostate cancer (HRPC). This number increased to 87% (121/139) at the time of spine surgery. Of patients who received RT prior to surgery, 45% (37/83) had HRPC at the time of MSD diagnosis and 88% (73/83) had progressed to HRPC at the time of surgery. Among patients with high-grade ESCC, 44% (56/126) had HRPC at MSD diagnosis and 89% (112/126) had HRPC at spine surgery (Table 2) .
Surgical Decision Making and Patient Characteristics at Time of Surgery
A total of 157 spine operations were performed on 139 patients. Of those, 91% (143/157) were performed for highgrade ESCC, while 9% (14/157) were performed for mechanical instability only. At the time of surgery, 46% (73/157) of lesions caused circumferential spinal cord compression on imaging. Of Intact  132  84  Incontinent  25  16  Mechanical pain  No pain  26  17  Pain  129  82  Unknown  2  1 the patients who had received RT to the operated levels, median time from RT to surgery was 352 d (range: 1-5298 d).
Of the 157 clinical presentations, 69% (108) involved motor deficits and 45% (70) involved sensory deficits; 6% (10) were bowel incontinent and 16% (25) were bladder incontinent (Table 3) . Overall, 82% (129) had mechanical pain. Nonambulatory patients accounted for 21% (33), while 47% (74) could walk with assistance and 31% (49) were ambulatory without assistance, and the ambulatory status of 1% (1) was unknown at the time of spine surgery. Among the nonambulatory patients, 24% (8/33) were unable to walk due to sensory deficits, 60% (20/33) due to motor deficits, and 12% (4/33) due to a combination of sensory and motor deficits. This information was not available for 1 patient. The majority of the patients were nonambulatory or had difficulty ambulating due to either pain (32%) or weakness (45%).
Surgical Details
Operated levels included 10% (16) cervical, 57% (89) thoracic, 17% (27) lumbar, and 10% (15) spanning junctional levels (7 cervicothoracic, 8 thoracolumbar; Table 4 ). Of 157 surgeries, 83% (130) involved separation surgery with instrumentation, 10% (15) involved laminectomy only, 4% (6) involved corpectomy with instrumentation, and 4% (6) had instrumented fixation without decompression. Intraoperative brachytherapy with P 32 plaque was given during 6% (9) of operations. Median operative time (including anesthesia time) was 195 min (range: 62-665). Median estimated blood loss was 800 cc (range: 50-9100 cc) with 58.6% of surgeries requiring postoperative transfusion. Median hospital stay was 9 d (range: 2-76 d).
Surgical Outcomes
Surgical treatment significantly improved nearly all measures of preoperative morbidity in patients with MSD requiring surgery (ie, those with symptomatic ESCC or mechanical instability). For 157 lesions in patients in whom both pre-and postoperative data were available, postoperative improvement was noted in 42% (44/105, P < .0001) of those with motor deficits, 62% (39/63, P < .0001) with sensory deficits, 75% (91/121, P < .0001) with mechanical instability pain, 75% (6/8 patients, P = .16) with bowel incontinence, and 82% (18/22, P < .05) with bladder incontinence. Of nonambulatory patients, 76% (25/33, P = .003) regained the ability to walk.
High-grade ESCC accounted for 91% (143/157) of the surgeries performed. In this cohort, surgical decompression significantly improved all measures of preoperative morbidity. Of lesions causing preoperative motor deficits, 42% (40/96, P < .0001) were motor intact postoperatively. Of lesions causing sensory deficits, 61% (33/54, P < .0001) regained normal sensation postoperatively. Of lesions causing mechanical pain, 72% (79/109) improved postoperatively. Bladder and bowel continence was regained in 80% (16/20, P = .06) and 75% (6/8, P = .06), respectively. Ambulation was regained in 78% (25/32, P = .0015), with 65% (21/32) ambulating with assistance and 12.5% (4/32) ambulating independently (P = .0004).
Mechanical instability without high-grade ESCC accounted for 9% (14/157) of surgeries. Of those, 86% (12/14) presented with mechanical pain, all of whom improved after surgical stabilization.
Postoperative Radiation
Postoperatively, 52% (77/148) of unique lesions were irradiated. This included cEBRT in 58% (45) of lesions (median dose: 3000 cGy in 10 fractions) and SRS for 42% (32) of lesions (median dose: 2400 cGy in 3 fractions). The majority of patients who did not receive postoperative RT had been irradiated prior to the evolution of SRS, which allows for reirradiation, or had a large systemic disease burden.
New Postoperative Deficits and 30-d Complications
Of those intact preoperatively, 17% ( of patients experienced adverse events that required readmission. These included 6 wound infections/dehiscence with 2 requiring washout and repair, 1 case of early hardware failure requiring reoperation, 1 CSF leak requiring operation, 1 epidural abscess requiring drainage, and 2 cases each of pneumonia and urinary tract infection.
Recurrences and Overall Survival
Of 139 patients who underwent 157 operations, 9 procedures were performed for recurrent disease while new lesions accounted for another 9 procedures. At the end of the study period, 21 (15%) patients were still alive. Median follow-up was 6.7 mo for the entire cohort and 8.1 mo for survivors.
Median OS for the entire cohort was 7.5 mo (95% confidence interval [CI]: 6.1-10.2 mo). When dichotomized according to hormone responsiveness at the time of surgery, patients with HRPC had a median OS of 6.6 mo (95% CI: 5.6-8.6), while the median OS of hormone-sensitive patients was 16.3 mo (95% CI: 4.0-26.6; log-rank P = .06; Figures 2A and 2B ).
DISCUSSION
Prostate cancer is the second most common cause of MSD, 19 with over 95% having adenocarcinoma histology. 20 With the advent of routine PSA screening, the incidence of metastatic prostate cancer as the first presentation of disease has fallen to approximately 7%. 21 Newly diagnosed metastatic prostate cancer is highly sensitive to androgen deprivation therapy (ADT) 10, 20 ; for these hormone-naïve cases, ADT along with EBRT has been proposed as a viable first-line treatment option. 8 The use of hormone therapy, in contrast to surgical castration, has been in practice in the United States for over 6 decades. Antiandrogen therapy for prostate cancer was first described in the 1960s, with subsequent widespread use of androgen ablation through nonsteroidal antiandrogens starting with the FDA approval of flutamide in 1989. 22 With time, however, prostate cancer becomes resistant to hormonal treatment; HRPC 10 is the most common type of prostate cancer with MSD, with significantly increased morbidity and mortality. 9 The OS of patients with metastatic HRPC is between 2 and 3 yr. [23] [24] [25] Moreover, long-term ADT can cause osteoporosis 26, 27 and contribute to disease progression in the spine. Spine metastasis from prostate cancer typically presents as a sclerotic lesion ventrally infiltrating vertebral bodies of the thoracolumbar spine. 28, 29 In the absence of high-grade ESCC causing acute neurological morbidity or mechanical instability, these tumors can safely be treated with EBRT or ADT. In prostate cancer patients with MSD who were surgical candidates, surgery was shown to improve functional outcome, ie, recover ambulation 12, 16 and continence 12, 13, 16 and reduce the amount of corticosteroid and narcotic use.
12,13
Surgical Indications
In the current series, surgical indications included epidural progression of previously irradiated metastases and spinal cord compression causing progressive neurological deficit or mechanical instability. Patients without these surgical indications initially underwent RT or ADT in order to treat MSD. Surgical decompression among patients with symptomatic ESCC has been shown to provide superior outcomes when compared to RT without surgery. 7 Therefore, among patients with progressive neurological deficits, decompression is preferred to RT in order to provide rapid spinal cord decompression and to optimize their chances of neurological recovery. In the current series, 69% of patients had motor deficits prior to undergoing surgery, with many additional patients experiencing sensory, bowel, or bladder control deficits. Furthermore, 82% of patients had mechanical pain. Mechanical instability represents an independent surgical indication, as RT and systemic therapy cannot restore mechanical integrity of the spine. Spinal instrumented stabilization effectively restores spinal stability and can be carried out using open or minimally invasive surgical techniques.
Prostate metastases to the spine readily and reliably respond to radiotherapy. In patients without previous radiation or mechanical instability, cEBRT provides effective local control and can be administered in patients without spinal cord compression as well as in patients with spinal cord compression without neurological deficits. In the current patient series, 61% of patients underwent RT as the initial treatment for MSD, with 86% of these patients receiving cEBRT. Among these patients, the median time from RT to local progression requiring surgery was 1 yr. Among patients who underwent RT as the initial treatment, the number of HRPC patients increased from 45% at the time of RT to 88% at the time of surgery, indicating transformation to a more aggressive form of disease. Image-guided spinal reirradiation has been shown to provide effective tumor control, but care must be taken not to exceed safe spinal cord doses. Therefore, in patients with epidural tumor progression in a previously irradiated field, spinal cord decompression should be carried out in order to safely deliver effective reirradiation doses.
As evidenced by the current series, the overwhelming majority of patients with hormone-sensitive prostate cancer do not require spinal surgery. In the current study, 87% of patients undergoing spinal surgery for the treatment of prostate metastases had HRPC. This number was even higher (89%) in patients with high-grade ESCC. Notably, fewer than half of patients had HRPC at the time of MSD diagnosis. Furthermore, a significant number of these patients presented with neurological deficits attributable to spinal cord compression, indicating the aggressive nature of this disease. Transformation to HRPC puts patients at risk for developing symptomatic spinal cord compression and requires careful monitoring for signs and symptoms of spinal tumor progression. HRPC also portends poor survival prognosis for patients undergoing spinal surgery, with patients with hormonesensitive disease at the time of surgery living much longer than those with HRPC.
Surgical Outcomes and Complications
As expected, surgical treatment significantly improved nearly all measures of preoperative morbidity in patients with MSD requiring surgery (ie, those with symptomatic ESCC or mechanical instability). Forty-two percent of patients with preoperative motor deficits experienced motor improvement, 62% experienced sensory improvement, and 76% of nonambulatory patients recovered ability to ambulate. Furthermore, 75% of patients with mechanical instability experienced significant pain improvement.
The overall 30-d complication rate of 15.9% in our study compares favorably to that reported in the literature. 5, 11, [13] [14] [15] [16] 12 The rate of postoperative motor deterioration was 2% in our study. In a cohort of 678 patients with primary and metastatic spine tumors, the rate of surgical site infection for metastatic spinal tumors was 9.5%, 30 with prior surgery, complex plastics closures, and hospital-acquired infection at the time of previous surgery as significant determinants on multivariate analysis. However, our own experience with reoperation for recurrent ESCC at the same level of prior surgery showed a 5% major complications rate. 31 Jansson et al 15 reported an overall complication rate of 20% in their cohort of 282 patients (40% metastatic prostate).
15
Limitations
The major limitation of this study lies in its retrospective nature. Additionally, not all patients were diagnosed at our institution, and we also recognize that there may have been others with similar progression who were diagnosed at our institution but sought follow-up treatment elsewhere. The current patient group describes a subgroup of patients with prostate cancer who required spinal surgery. The current results cannot provide conclusive information about the risk of symptomatic spinal cord compression or mechanical instability in patients with prostate cancer as a whole. However, the significant number of patients presenting with motor deficits emphasizes the importance of heightened vigilance in patients with HRPC.
CONCLUSION
Patients with HRPC with MSD are at risk of epidural tumor progression. The purpose of this analysis was to delineate the characteristics of the patient population undergoing surgery for the treatment of prostate cancer metastatic to the spine. Patients with hormone-sensitive prostate cancer constitute a very small proportion of patients undergoing spinal surgery for the treatment of prostate MSD and are unlikely to require spinal surgery. On the other hand, 87% of patients in the current surgical series had HRPC, indicating that these patients represent a group at risk for requiring surgical intervention for the treatment of MSD. The high proportion of patients presenting with motor and sensory deficits emphasizes the aggressive nature of HRPC disease and indicates that this patient population requires close surveillance for the development of signs and symptoms of ESCC and spinal instability. Furthermore, patients with HRPC have significantly shorter postoperative survival when compared to patients with hormone-sensitive cancer, and this may affect surgical decision making and operative planning.
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